{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:02:25Z","timestamp":1785373345163,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13300-023-01506-1","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:01:40Z","timestamp":1699678900000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?"],"prefix":"10.1007","volume":"15","author":[{"given":"Evanthia","family":"Gouveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type\u00a02 diabetes\u2014state-of-the-art. Mol Metab. 2021;46: 101102.","journal-title":"Mol Metab"},{"key":"1506_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type\u00a02 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"1506_CR4","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type\u00a01 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39:1702\u201310.","journal-title":"Diabetes Care"},{"key":"1506_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahr\u00e9n","year":"2016","unstructured":"Ahr\u00e9n B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type\u00a01 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39:1693\u2013701.","journal-title":"Diabetes Care"},{"key":"1506_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12020-022-03294-3","volume":"80","author":"DS Popovic","year":"2023","unstructured":"Popovic DS, Stoian AP, Papanas N. Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type\u00a01 diabetes mellitus? Endocrine. 2023;80:232\u20133.","journal-title":"Endocrine"},{"key":"1506_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1570161121666230817105105","volume":"21","author":"DS Popovic","year":"2023","unstructured":"Popovic DS, Koufakis T, Papanas N. The recent trends in all-cause and cardiovascular mortality among people with type\u00a01 diabetes mellitus\u2014success is still far away, and we must do better! Curr Vasc Pharmacol. 2023;21:219\u201321.","journal-title":"Curr Vasc Pharmacol"},{"key":"1506_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMc2302677","volume":"389","author":"P Dandona","year":"2023","unstructured":"Dandona P, Chaudhuri A, Ghanim H. Semaglutide in early type\u00a01 diabetes. N Engl J Med. 2023;389:958\u20139.","journal-title":"N Engl J Med"},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1055\/a-1392-0590","volume":"130","author":"DS Popovic","year":"2022","unstructured":"Popovic DS, Papanas N. Double diabetes: a growing problem requiring solutions. Exp Clin Endocrinol Diabetes. 2022;130:268\u201374.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1506_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324.","journal-title":"N Engl J Med"},{"key":"1506_CR11","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/nu14214673","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M, et al. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type\u00a02 diabetes: a 52-week prospective real-life study. Nutrients. 2022;14:4673.","journal-title":"Nutrients"},{"key":"1506_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase\u00a02 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1506_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849","volume":"17","author":"S Bandyopadhyay","year":"2023","unstructured":"Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17:102849.","journal-title":"Diabetes Metab Syndr"},{"key":"1506_CR14","unstructured":"ClinicalTrials.gov. NCT04822181. https:\/\/www.clinicaltrials.gov\/study\/NCT04822181?cond=NAFLD&term=ESSENCE&rank=1. Last accessed 22 Sept 2023."},{"key":"1506_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","volume":"81","author":"YF Chang","year":"2020","unstructured":"Chang YF, Zhang D, Hu WM, et al. Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020;81:234\u20139.","journal-title":"J Clin Neurosci"},{"key":"1506_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, Li XR, Chai SF, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology. 2023;240: 109716.","journal-title":"Neuropharmacology"},{"key":"1506_CR17","unstructured":"ClinicalTrials.gov. NCT04777396. https:\/\/clinicaltrials.gov\/study\/NCT04777396?cond=Alzheimer%20Disease&term=Semaglutide&rank=3. Last accessed 8 Oct 2023."},{"key":"1506_CR18","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/biomedicines10071661","volume":"10","author":"LS Dalb\u00f8ge","year":"2022","unstructured":"Dalb\u00f8ge LS, Christensen M, Madsen MR, et al. Nephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease. Biomedicines. 2022;10:1661.","journal-title":"Biomedicines"},{"key":"1506_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","volume":"103","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR, Bosch-Traberg H, Cherney DZI, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type\u00a02 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103:772\u201381.","journal-title":"Kidney Int"},{"key":"1506_CR20","unstructured":"ClinicalTrials.gov. NCT03819153. https:\/\/clinicaltrials.gov\/study\/NCT03819153?cond=Renal%20disease&term=Semaglutide&rank=5. Last accessed 8 Oct 2023."},{"key":"1506_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","volume":"15","author":"M Yu","year":"2023","unstructured":"Yu M, Wang R, Pei L, et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15:164.","journal-title":"Diabetol Metab Syndr"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-023-01506-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T03:41:31Z","timestamp":1705117291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-023-01506-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s13300-023-01506-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer-Ingelheim. Djordje S. Popovic declares associations with: Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and W\u00f6rwag Pharma Nikolaos Papanas has been an advisory board member of AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}}]}}